{
    "clinical_study": {
        "@rank": "122715", 
        "arm_group": [
            {
                "arm_group_label": "Tofacitinib (Xeljanz)", 
                "description": "Tablets 5 mg BID"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "description": "Standard of Care for Rheumatoid Arthritis"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this Surveillance is to verify the following subject matters concerning\n      Tofacitinib (Xeljanz) under general practice.\n\n      1)    Occurrence of adverse reactions, factors that may potentially affect safety and\n      efficacy 2\uff09 Long-term safety (particularly, malignant tumors and serious infections) and\n      efficacy\n\n      Occurrences of malignant tumors and serious infections will be compared with a control\n      group."
        }, 
        "brief_title": "Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "All the patients whom an investigator prescribes the Xeljanz or Standard of Care for\n      rheumatoid arthritis should be registered consecutively until the number of subjects reaches\n      target number in order to extract patients enrolled into the investigation at random."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients receiving Tofacitinib (Xeljanz)\n\n        Exclusion Criteria:\n\n        Not Applicable"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients with moderately to severely active rheumatoid arthritis who have had an\n        inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment."
            }
        }, 
        "enrollment": {
            "#text": "6000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932372", 
            "org_study_id": "A3921194"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tofacitinib (Xeljanz)", 
                "description": "5 mg Tablet BID", 
                "intervention_name": "Tofacitinib (Xeljanz)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "description": "Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly", 
                "intervention_name": "Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "TNFR-Fc fusion protein", 
                "Antirheumatic Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "Good Post Marketing Study Practice", 
            "Tofacitinib", 
            "Xeljanz", 
            "Regulatory Post Marketing Commitment Plan"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921194&StudyName=Tofacitinib%20%28Xeljanz%29%20Special%20Investigation%20for%20Rheumatoid%20Arthritis"
        }, 
        "number_of_groups": "2", 
        "official_title": "Tofacitinib (Xeljanz Tablets 5 mg) Long Term Special Investigation for Rheumatoid Arthritis (Regulatory Post Marketing Commitment Plan)", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Foundation for Biomedical Research and Innovation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 \u22643.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.", 
                "measure": "Disease Activity Score Based on 28-joints Count (DAS28)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.  An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.", 
                "measure": "Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "36 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932372"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}